National Agri-Marketing Association
NAMA Website
Upcoming Events
Agri-Marketing Conf
Best of NAMA 2017
Member Directory

Source: Merck news release

To view the complete report, click here.

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2014.

"Investing in the best opportunities for growth while being disciplined in managing our costs enabled us to deliver bottom-line performance," said Kenneth C. Frazier, chairman and chief executive officer, Merck.

"This is an exciting time as we prepare to commercialize the next wave of innovation coming out of Merck's research labs over the next few years."

Animal Health Revenue Performance

Animal Health sales totaled $813 million for the first quarter of 2014, a 3 percent decrease compared with the first quarter of 2013, including a 3 percent negative impact due to foreign exchange.

The results reflect the company's decision last year to voluntarily suspend sales of ZILMAX (zilpaterol hydrochloride), a feed supplement for beef cattle, in the United States and Canada.

Excluding sales of ZILMAX, Animal Health sales increased 5 percent in the first quarter, driven by higher sales of poultry, swine and aqua products.

In the first quarter, the European Commission granted marketing authorization for BRAVECTO (fluralaner), a chewable tablet that kills fleas and ticks in dogs for up to 12 weeks; the company anticipates approval in the United States later in 2014.

Search News & Articles

Proudly associated with:
American Business Media Canadian Agri-Marketing Association National Agri-Marketing Association
Agricultural Relations Council National Association of Farm Broadcasters American Agricultural Editors' Association Livestock Publications Council
All content © 2018, Henderson Communications LLC. | User Agreement